Kornimate/medical-research-clean huggingface dataset:
retrospective study on the evolution of cin 1 to 3 in per and postpartum in nancy from 2014 to 2022

Conditions: Cervical Intraepithelial Neoplasia

Summary: in france, the screening rate for cervical cancer remains too low. screening is simple and non-invasive. pregnant patients are most of the time young and are part of the target population for screening, and for many women, it is the first encounter with a gynecologist. the cervical smear is therefore an important step of the first consultation during pregnancy in the case of pathological results, colposcopies with biopsies are performed, frequently finding cin 1 to 3. (cervical intraepithelial neoplasia) these cin lesions evolve slowly and most of the time, treatment can be withheld until the end of the pregnancy. several studies suggest a higher regression rate in pregnant patients. our study will evaluate the rate of regression, progression or persistence of these lesions in per and post partum patients in nancy, between 2014 and 2022. to obtain our results, we will compare the results of per and post partum biopsies in each patient. in a second step, we will study the risk factors of aggravation or on the contrary the protective factors, allowing a faster regression of the lesions


Eligibility criteria:
inclusion criteria: * women who have a cin lesion during pregnancy * in nancy, france, mrun center * between 2014 and 2022 exclusion criteria: * lost of follow up women
calprotectin in chronic prosthetic joint infection

Conditions: Prosthetic Joint Infection; Prosthetic Infection; Arthroplasty Complications

Summary: a bacterial infection of an artificial joint is a serious complication that often requires additional surgery to exchange the arthroplasty. it is also difficult to recognize an infected joint, as the symptoms caused by the infection are very similar to those of other problems with arthroplasties, such as loosening of the implant. to improve the ability to diagnose prosthetic joint infections, this study compares the levels of calprotectin, a specific inflammatory protein, in the joint fluid of infected joints and joints with other complications. the underlying hypothesis is that the level of calprotectin in infected joints is significantly higher, thus facilitating the diagnosis of prosthetic joint infection.


Eligibility criteria:
inclusion criteria: * scheduled arthroplasty exchange for any of the following reasons: * infection * loosening * instability * malalignment * periprosthetic fracture exclusion criteria: * acute prosthetic joint infection
safety and effectiveness of capsulotomy in refractory ocd

Conditions: Obsessive-Compulsive Disorder

Summary: obsessive-compulsive disorder (ocd) is a severely disabling psychiatric disorder with a worldwide lifetime prevalence of 2-3% (islam et al., 2015).despite the efficacy of pharmacological and behavioural treatment methods for most ocd patients, roughly one third do not demonstrate significant symptom improvement, even after aggressive treatment (foa et al, 2007). the effectiveness of neurosurgical treatment methods (including ablative surgery) for those with severely disabling treatment resistant ocd is substantiated by clinical research (greenberg, rauch \& haber, 2010). the brain target of this procedure is usually the area between the anterior and middle third of the anterior limb of the internal capsule.


Eligibility criteria:
inclusion criteria: 1. obsessive compulsive disorder as the primary psychiatric diagnosis (according to dsm iv-criteria). 2. severity: score higher than 25 on the yale-brown obsessive compulsive scale (y-bocs). 3. course of illness had to have been present for at least five years in a chronic or progressive form despite any treatment trials (refractory). 4. refractory: a lack of response to drug therapy after adequate administration (defined as more than 12 weeks at the maximum tolerated dose) of at least three serotonin-reuptake inhibitors, and clomipramine. adequate psychotherapy, defined as continuously treatment for more than six months with a certified therapist . exclusion criteria: 1. schizophrenic disorder; bipolar disorder; substance abuse or dependence (except for dependence on nicotine), as assessed with the use of the mini-international neuropsychiatric interview (mini 6.0.0); 2. cluster a or b personality disorder according to dsm-iv criteria, as assessed with the use of the structured clinical interview ii. 3. a current severe major depressive episode, determined according to dsm-iv criteria (as assessed with the use of the mini 6.0.0) and defined by hamd-17 score of more than 20 and a risk of suicide. 4. abnormal cognitive status (measured by moca)

Keywords: neurosurgery capsulotomy
low-level laser therapy in the treatment of chronic periodontitis in type 2 diabetics

Conditions: Chronic Periodontitis; Diabetes Mellitus

Summary: the aim of this study was to investigate the local effect of adjunct low-level laser therapy (lllt) for the treatment of moderate to severe chronic periodontitis in type 2 diabetic patients.

the aim of this study was to investigate the local effect of adjunct low-level laser therapy (lllt) for the treatment of moderate to severe chronic periodontitis in type 2 diabetic patients. twenty poorly-controlled type 2 diabetic patients with moderate to severe generalized chronic periodontitis were selected. two periodontal pockets with probing depth (pd) and clinical attachment level (cal) ≥ 5mm received ultrasonic periodontal debridement (upd) only (control group) or upd with lllt (test group). clinical measures, such as pd, cal, gingival recession (gr), bleeding on probing (bop), and plaque index (pi), were collected and compared at baseline, 30, 90, and 180 days. the adjunct application of lllt to upd had no additional benefits for pd reduction and cal gain, meaning that both investigated therapies were efficient for the treatment of chronic periodontitis in type 2 diabetics. nevertheless, additional lllt application showed better results for gr then upd only.

Eligibility criteria:
inclusion criteria: * age ≥ 35; diagnosis of type 2 diabetes for ≥ 5 years; diabetes treatment with oral hypoglycemic agents or insulin supplementation and diet; glycated hemoglobin (hba1c) levels from 6.5% to 11%; at least 15 teeth (excluding third molars and teeth indicated for extraction); and moderate to severe generalized chronic periodontitis. exclusion criteria: * the exclusion criteria were: medical conditions that required prophylactic antimicrobial coverage; periodontal mechanical therapy in the previous 6 months; antimicrobial therapies in the previous 6 months; anti-inflammatory therapies in the previous 6 months; systemic conditions other than diabetes that could affect the progression of chronic periodontitis; current use of medication that could interfere with periodontal response to treatment; pregnancy or lactation; and smoking.

Keywords: periodontal treatment low-level light therapy
validation and comparison of the appendicitis inflammatory response score and adult appendicitis score

Conditions: Acute Appendicitis; Acute Appendicitis With Rupture

Summary: acute appendicitis is one of the most frequent reasons of emergency laparotomy in adults. symptoms of acute appendicitis overlap with other clinical conditions and might present as a challenge, especially in the early phases. despite the advances and widespread use of imaging modalities, still negative laparotomies are performed with the initial diagnosis of acute appendicitis. several scoring systems are developed by using various clinical and laboratory parameters in order to improve the diagnostic accuracy and prevent unnecessary laparotomies.

in the recent guideline of world society of emergency surgeons (wses) recommendations regarding the clinical scoring systems for acute appendicitis are remarkable. it is stated that clinical scoring systems, on their own, can be used to exclude acute appendicitis and decrease negative laparotomy rates. currently appendicitis inflammatory response score (air) and adult appendicitis score (aas) are the best clinically performing scoring systems. as a result, based on strong evidence the use of these two systems are recommended. both scoring systems are developed on the basis of clinical findings and laboratory parameters. the aim of this study is to validate both systems as well as to compare the efficiency of both systems on excluding negative laparotomies and on the determination of severity of acute appendicitis.

Eligibility criteria:
inclusion criteria: * presenting to er with right lower quadrant pain * patients between 18-65 years old. exclusion criteria: * patients receiving immun-suppressive therapy * patients with diagnosed malignancy * presence of mental retardation * patients with previous right hemicolectomy * patients with previous appendectomy * pregnant women
community and familial impacts of the opioid crisis

Conditions: Opioid Use Disorder; Bereavement; Overdose of Opiate

Summary: this study aims to analyze the needs of those who have lost a loved one to opioid-related death and/or those currently supporting a loved one in treatment for opioid use disorder. mental health status related to the death or support of a loved one will be assessed through a survey and through the use of several modules of the cat-mh (computerized adaptive testing-mental health suite) questionnaire.

this study aims to establish the level of needs in the community among those who have lost loved ones to opioid overdose and/or currently support those in opioid addiction recovery. this study aims to analyze the needs of those who have lost a loved one to opioid-related death and/or those currently supporting a loved one in treatment for opioid use disorder. the study will evaluate the mental health status for each study participant through a primary survey as well as current participant mental health status through the use of several modules of the cat-mh adaptive testing questionnaire. cat-mh will be used to rapidly measure severity levels of depression, anxiety, and substance use risk after participants complete the primary survey. the primary survey assesses the immediate impact of overdose death by a loved one and recognition of the onset of opioid addiction in the years after the event on family and community members. the primary survey will compare the impact of loss and/or recovery support on mental health and substance use at specified time points before and after the loss and/or an individual finding out about a loved one's opioid addiction. the primary survey will also evaluate attitudes in this population about mindfulness and self-compassion skills training, openness to technology and various treatment options, current and past levels of depression, anxiety and grief, as well as thematic areas of need specific to those who have lost a loved one to opioid overdose and/or currently support a loved one in opioid addiction recovery.

Eligibility criteria:
inclusion criteria: * aged 18+, inclusive, who are competent, wish to participate and willing to provide informed consent * willing and able to participate in completing the surveys using the internet on via smartphone as requested * identify in one of the 3 groups: (a) adults who have lost a direct relative or friend to opioid overdose or opioid-related death prior to taking the survey; (2) adults who are currently supporting a loved one with active opioid addiction; (3) adults who have lost a direct relative or friend to opioid overdose or opioid related death at least six months prior to survey participation and also currently support a loved one in active addiction recovery. exclusion criteria: * inability to complete the survey * inability to speak, read, and understand english
preventing esophageal stent migration in esophageal strictures

Conditions: Stent Migration

Summary: this study aims to assess the efficacy and rate of stent migration in standard of care esophageal stents that are not fixed, compared to those that are fixed with either standard of care otsc stentfix or standard of care stent placement with suturing in both benign and malignant esophageal strictures.


Eligibility criteria:
inclusion criteria: 1. the study population will include any adult (18 years +) who will undergo standard of care esophageal stent placement for benign or malignant esophageal strictures as either an inpatient or outpatient at nyulh. 2. the participant is able to consent to stent placements with fixation or without fixation and study procedures, verified by signature on the informed consent form. 3. willing to comply with all study procedures and be available for the duration of the study. 4. english and non-english speaking participants. exclusion criteria: 1. patients who have strictures treated with luman apposing stents.
a long-term, continued treatment and follow-up study in participants with hematologic malignancies treated with duvelisib (ipi-145)

Conditions: Hematologic Malignancy

Summary: this was a long-term, continued treatment study that evaluated the long-term safety, clinical activity, and overall survival (os) of duvelisib in individuals with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.

study ipi-145-23 was an international, multicenter, open-label, single-arm, phase 2 study designed to evaluate the long-term safety, clinical activity, and overall survival data of duvelisib in individuals with hematologic malignancies. only individuals who have participated in a previous duvelisib study that were approved by the sponsor were allowed to enroll in the study. participants in active treatment and participants in survival follow-up were allowed to rollover to this study. for participants on active treatment, participants continued the same dose from their previous duvelisib study administered twice daily for 28-day continuous cycles until disease progression or unacceptable toxicity and then followed in a survival follow-up period. for participants in survival follow-up, participants continued to be followed-up for survival in this study for the duration as outlined in their previous duvelisib study.

Eligibility criteria:
inclusion criteria: * have participated in a previous study of duvelisib, and: * be actively receiving duvelisib monotherapy on the previous study (within 14 days of study entry) and demonstrating clinical benefit (complete response \[cr\]/ partial response \[pr\]/ stable disease \[sd\]) of continued use, or * be in the survival follow-up phase of a previous duvelisib study * have completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the sponsor exclusion criteria: * had any ongoing ≥ grade 3 adverse event (ae) considered related to duvelisib treatment at screening * was pregnant or nursing
rasagiline rescue in alzheimer's disease clinical trial

Conditions: Alzheimer's Disease

Summary: this is a phase ii, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of rasagiline in the regional brain metabolism on 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (fdg-pet).

the study consists of two phases: a 24 week double blind placebo controlled treatment period and a 4 week follow up period. patients will be randomized in a 1: 1 ratio at baseline to receive either rasagiline or matching placebo the study drug will be given as 0.5 mg dose once daily for the 4 weeks, then increases to 1 mg daily for the next 20 weeks. a total of 50 subjects will be enrolled: 25 will receive rasagiline and 25 will receive matching placebo for the 24-week treatment period. primary objective is to determine if exposure to 1 mg of rasagiline daily is associated with improved regional brain metabolism in the treatment group compared to the placebo group in alzheimer's disease patients

Eligibility criteria:
inclusion criteria: * males or females 50 to 90 of age inclusive. * diagnosis of probable ad (nincds-adrda criteria) * positive fluoro-deoxyglucose pet (\[18f\]-fdg pet) scan compatible with ad as determined by the adm diagnostics llc (admdx) criteria at screening * mini mental status exam = 12 - 22 (inclusive) * must have a study partner who is able and willing to comply with all required study procedures. * have at least eight years of education and should have previously (in pre-ad condition) been capable of reading, writing, and communicating effectively with others in english. * if receiving therapy with a cholinesterase inhibitor and/or memantine, the dose of these agents has been stable for at least 3 months prior to screening exclusion criteria: * any non-ad neurological disease * mri findings indication of a non-ad diagnosis * screening laboratory studies that are 1.5 times above or below the highest and lowest range of normal for each test respectively * history of melanoma; history of malignancy within the past five years with the exception of basal cell or squamous cell cancer, in-situ cervical cancer, or localized prostate cancer
hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the preventive lymphadenectomy is not performed routinely for hepatocellular carcinoma (hcc) patients in clinical practice. while many patients suffered the recurrence without the evidence of portal or hepatic vascular invasion or multiple loci, it lead to reconsider the value of preventive resection of regional lymph node for those patients. recently, more and more studies had found the incidence of lymph node metastasis was higher in autopsy specimen than those in operable patients. this project is a prospective randomized controlled trial, planning to compare hepatectomy with hepatectomy combined lymphadenectomy regarding of the safety and efficacy in hcc patients, to reach a further understanding of the role of lymphadenectomy.


Eligibility criteria:
inclusion criteria: * age 18 to 65 years; * eastern cooperative oncology group (ecog) performance status is grade 0 or 1; * good liver function with pugh-child class a or b; * indocyanine green retention at 15 minutes (icg-r15) \<15%; * without severe cirrhosis; * the diameter of tumor is equal to or more than 3 cm; * the liver resection could be assessed r0 (the define of r0 resection will be explained in the section of surgical procedures); * absence of extrahepatic metastasis. exclusion criteria: * the diameter of tumor is less than 3 cm; * palliative resection of tumor; * with the history of hepatic encephalopathy, ascites, and variceal bleeding; * with severe hepatic cirrhosis; * tumor rupture; * with the history of upper abdominal surgery, it is tough to remove the regional lymph nodes; or it is unable to be resected when multiple lymph nodes mixed and fixed.

Keywords: hepatocellular carcinoma hepatectomy lymphadenectomy complication prognosis
genetic markers of coronary heart disease in type 2 diabetes

Conditions: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Non-insulin Dependent; Diabetes Mellitus; Heart Diseases

Summary: to investigate genetic markers of coronary heart disease in type 2 diabetes.

background: coronary heart disease (chd), as the leading cause of death in the united states, is of significant public health concern. despite the knowledge that atherosclerosis is the underlying cause of chd, the recognition that both genetic and environmental factors contribute to the occurrence of disease, and the identification of a large number of genetic and environmental factors that have been found to be associated with disease risk, the etiology of atherosclerosis with the later development chd continues to be not very well understood. design narrative: the nested case-control study will determine whether variability in 20 genes belonging to endothelial and inflammatory dysfunction pathways is related to the risk of coronary heart disease (chd) among men and women diagnosed with type 2 diabetes in two large ongoing prospective studies, the nurses' health study (nhs) and health professionals' follow-up study (hpfs). this will be accomplished by combining two complementary approaches that are made possible by the recent advances in knowledge of the human genome and high-throughput genotyping technologies. the investigators will directly target functional variants in the coding regions of the candidate genes and also investigate the association between chd and ancestral haplotypes at each locus. the specific aims are: 1. to identify novel variants in 10 candidate genes of the inflammatory, and endothelial dysfunction pathways that have not been systematically screened for polymorphisms by targeted resequencing; 2. to assess the relationship between functional variants in 20 candidate genes in the inflammatory and endothelial dysfunction pathways and risk of chd among subjects with diabetes of the nhs and hpfs cohorts; 3. to identify the subset of polymorphisms that best capture the overall genetic variability at each locus (haplotype tagging single nucleotide polymorphisms (snps) or htsnps) and investigate the association between chd risk and the haplotypes defined by these htsnps; 4. to examine individual snps as well as haplotypes in relation to biochemical markers of inflammation and endothelial activation such as crp, icam-1, vcam-1, e-selectin, and tnf-a in diabetic individuals; and 5. to examine gene-environment interactions in relation to chd risk in diabetic subjects. by 2006, an estimated 820 cases of chd will have been confirmed among diabetic men and women in the blood cohorts. the large size, prospective design, high follow-up rates, detailed and reliable long-term lifestyle and outcome information, and the availability of blood specimens make these cohorts a valuable and unique resource for studying genetic determinants of accelerated atherosclerosis in diabetic patients.

Eligibility criteria:
no history of cvd or cancer at baseline